ARCHIVES

Includes May issue of Business & Regulatory Report.

This article is from The Cancer Letter archive.

Vol. 28 No. 22 | May 31, 2002

Download PDF Visit The Full Archive

Related Articles

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

November 5, 2004

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

March 30, 2001

CIS Cost Sharing Feasibility Study Recommended

December 11, 1987

NCI Predicts 42 Percent Increase In Number of Senior Survivors

October 28, 2011

Karen Antman recruited to NCI on an IPA to oversee changes to centers, SPORE programs.

October 31, 2003